Teva's extended-release risperidone for schizophrenia sees 5-point boost
Teva's long-acting schizophrenia drug hits goal in phase 3 | Fierce Pharma
Veterans' treatment discontinuation differs by type of antipsychotic
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
Teva Pharm May Pay as Much as $3.6 Billion in US Opioid Settlement
Yo-Bio on Twitter: "$TEVA will compete in the risperidone Extended-Release market with $JNJ (risperdal consta- every 2 weeks, INTRAMUSCULAR) and $INDV (PERSERIS- every 4 weeks, subcutaneous). if Teva regimen and efficacy will
PROPOSAL FOR THE ADDITION OF RISPERIDONE LONG-ACTING INJECTION AND PALIPERIDONE PALMITATE 1-MONTH LONG-ACTING INJECTION FOR THE
Positive Results From Trial of Risperidone Injectable Schizophrenia Treatment
Teva Denied On LAI Risperidone But Expected To Bounce Back 'Quickly' :: Generics Bulletin
Buy Teva Pharmaceuticals amid positive news, Bernstein says
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia | Business Wire
FDA declines to approve Teva-MedinCell's risperidone injection for treating schizophrenia | Seeking Alpha
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
Risperidone extended-release injectable suspension | MDedge Psychiatry
Teva Denied On LAI Risperidone But Expected To Bounce Back 'Quickly' :: Generics Bulletin
/cloudfront-us-east-2.images.arcpublishing.com/reuters/Q3V76PIRQBKVFCT4F2KKAGPMDE.jpg "Drugmaker Teva may pay as much as $3.6 billion in U.S. opioid settlement | Reuters")
Drugmaker Teva may pay as much as $3.6 billion in U.S. opioid settlement | Reuters
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation | Schizophrenia
Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders | SpringerLink
Teva, MedinCell Schizophrenia Drug Delayed over FDA Concerns | BioSpace
Risperidone extended-release injectable suspension | MDedge Psychiatry
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
Teva Upbeat On Risperidone Results :: Generics Bulletin
Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | Fierce Pharma
